MedPath

Effect of Lacidipine and Losartan on 24 Hour Systolic Blood Pressure Variability in Elderly Hypertensive Patients

Phase 4
Conditions
Hypertension
Registration Number
NCT00533858
Lead Sponsor
Seoul National University Hospital
Brief Summary

The aim of this study is to evaluate the effect of lacidipine and losartan in elderly hypertensive patients on reducing the 24 hour systolic BP variability, which is one of the potential parameter to consider in treating elderly hypertensive patients.

Detailed Description

In this study, we investigate the effects of two anti-hypertensive medications on systolic BP variability profile as a pilot study. This is a prospective, randomized, open-label, blinded end point (PROBE), parallel group study with two treatment arms. At the end of an initial 2-week washout period, during which any eventual anti-hypertensive drug is discontinued, patients fulfilling the inclusion criteria are randomly treated with the lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks. If the BP goal (SBP \< 140 mmHg and DBP \< 90 mmHg) has not been attained after 4 week's treatment, 12.5 mg hydrochlorothiazide (HCTS) once daily can be added.

Patients are checked 24-h ambulatory BP monitoring (ABPM) at the end of the washout period and after 12 weeks of active treatment. At each visit, seated cuff SBP and DBP, heart rate, use of concomitant medication and spontaneously reported adverse events are recorded.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
160
Inclusion Criteria
  • Elderly patients (age > 65 years)
  • Essential hypertension (systolic BP > 140 mmHg or diastolic BP > 90 mm Hg)
  • Provide written informed content
Exclusion Criteria
  • Secondary hypertension
  • Myocardial infarction or cerebrovascular accident within the preceding 6 months
  • Clinically significant valvular heart disease, heart failure (Class III, IV), renal insufficiency (serum creatinine > 2.5mg/dl), hepatic failure, uncontrolled diabetes mellitus
  • Known hypersensitivity to the drugs used in the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The change of 24-hour, one day systolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan group
Secondary Outcome Measures
NameTimeMethod
The change of 24-hour, one day diastolic BP standard deviation (SD) within subjects (the difference of SD before and after 12 weeks' treatment) in lacidipine group and losartan group
The difference of the changes in office diastolic and systolic BP after 12 weeks' treatment between lacidipine group and losartan group
The difference of the mean 24-hour ABPM systolic and diastolic BP after 12 weeks' treatment between lacidipine group and losartan group
The difference of the changes in pulse pressure after treatment between the 2 groups
The difference of the diastolic and systolic BP control rates after treatment between the 2 groups
The difference of the changes in 24-hour, one day BP standard deviation (SD) within subjects between lacidipine group and losartan group
The difference of the smoothness index (SI, dividing the average of the 24 hourly change after treatment by the corresponding standard deviation) between 2 groups
The difference of the variation of coefficient (CV) of the mean values (24-hour BP SD divided by the mean multiplied by 100) between 2 groups

Trial Locations

Locations (1)

Seoul National University Bundang Hospital

🇰🇷

Seongnam, Kyeonggi, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath